Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
11 2021
Historique:
received: 15 12 2020
revised: 26 04 2021
accepted: 07 05 2021
pubmed: 14 5 2021
medline: 17 3 2022
entrez: 13 5 2021
Statut: ppublish

Résumé

In acute myeloid leukemia (AML) with inv(3)(q21;q26) or t(3;3)(q21;q26), a translocated

Identifiants

pubmed: 33980539
pii: 2159-8290.CD-20-1793
doi: 10.1158/2159-8290.CD-20-1793
pmc: PMC8563373
mid: NIHMS1706253
doi:

Substances chimiques

GATA2 Transcription Factor 0
GATA2 protein, human 0
MDS1 and EVI1 Complex Locus Protein 0
MECOM protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2868-2883

Subventions

Organisme : NCI NIH HHS
ID : R01 CA204396
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK068634
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007899
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Blood. 2013 Mar 21;121(12):2289-300
pubmed: 23327922
Leukemia. 2018 Apr;32(4):882-889
pubmed: 29089643
Cancer Cell. 2014 Apr 14;25(4):415-27
pubmed: 24703906
Mol Cell. 2015 Jun 18;58(6):1028-39
pubmed: 25982114
Genome Biol. 2014;15(12):554
pubmed: 25476604
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Blood. 2011 Mar 31;117(13):3617-28
pubmed: 21289308
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17622-7
pubmed: 15585582
Genes Dev. 2011 Aug 1;25(15):1628-40
pubmed: 21828272
Mol Cell. 2020 Mar 19;77(6):1307-1321.e10
pubmed: 31954095
Nat Protoc. 2018 May;13(5):1006-1019
pubmed: 29651053
Blood. 2020 Jul 9;136(2):224-234
pubmed: 32219447
Cell. 1979 Oct;18(2):375-90
pubmed: 227607
Bioinformatics. 2010 Sep 1;26(17):2204-7
pubmed: 20639541
Nat Methods. 2020 Jul;17(7):708-716
pubmed: 32514112
Mol Cancer Ther. 2015 Jun;14(6):1276-85
pubmed: 25740244
Mol Cell Biol. 2006 Oct;26(19):7056-67
pubmed: 16980610
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Cell. 2019 May 16;177(5):1319-1329.e11
pubmed: 30955888
Nat Commun. 2018 Jan 9;9(1):110
pubmed: 29317678
Nat Rev Genet. 2016 Feb;17(2):93-108
pubmed: 26781813
Blood. 2017 Jun 15;129(24):3221-3226
pubmed: 28270453
Cell Stem Cell. 2010 Oct 8;7(4):532-44
pubmed: 20887958
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Nat Rev Cancer. 2008 Jul;8(7):523-34
pubmed: 18574464
Nat Genet. 2014 Dec;46(12):1258-63
pubmed: 25383969
Proc Natl Acad Sci U S A. 1992 May 1;89(9):3937-41
pubmed: 1570317
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D493-6
pubmed: 14681465
Blood. 2003 Feb 1;101(3):837-45
pubmed: 12393383
Elife. 2021 Feb 02;10:
pubmed: 33527899
PeerJ. 2016 Jul 19;4:e2209
pubmed: 27547532
Cell. 2014 Sep 11;158(6):1431-1443
pubmed: 25215497
Science. 2016 Mar 25;351(6280):1454-1458
pubmed: 26940867
Nat Med. 2014 Oct;20(10):1130-7
pubmed: 25194570
Blood. 2008 Apr 15;111(8):4329-37
pubmed: 18272813
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Cell. 2013 Mar 28;153(1):17-37
pubmed: 23540688
Dev Cell. 2005 Feb;8(2):153-66
pubmed: 15691758
Oncotarget. 2016 Dec 27;7(52):86300-86312
pubmed: 27863435
Nat Biotechnol. 2019 Mar;37(3):224-226
pubmed: 30809026
Cell. 2014 Apr 10;157(2):369-381
pubmed: 24703711
Blood. 2013 Oct 3;122(14):e12-22
pubmed: 23974199
Leukemia. 2014 Aug;28(8):1725-1735
pubmed: 24518206
J Clin Oncol. 2010 Aug 20;28(24):3890-8
pubmed: 20660833
Science. 2012 Sep 7;337(6099):1190-5
pubmed: 22955828
Nature. 2014 Jul 24;511(7510):428-34
pubmed: 25043047
Mol Cancer Ther. 2016 Dec;15(12):2905-2915
pubmed: 27707899
Blood. 2006 Aug 1;108(3):896-903
pubmed: 16597594
Cell. 1989 Jul 14;58(1):85-93
pubmed: 2665942
EMBO Rep. 2018 Apr;19(4):
pubmed: 29437775
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Blood Adv. 2019 Jul 9;3(13):2045-2056
pubmed: 31289032
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Nat Genet. 2016 Mar;48(3):265-72
pubmed: 26829750
Dis Model Mech. 2019 Nov 26;12(11):
pubmed: 31771951
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Nature. 2002 Oct 17;419(6908):738-43
pubmed: 12384703
Sci Adv. 2015 Sep 04;1(8):e1500503
pubmed: 26601269
Science. 2014 Dec 12;346(6215):1373-7
pubmed: 25394790

Auteurs

Leonie Smeenk (L)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Sophie Ottema (S)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Roger Mulet-Lazaro (R)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Anja Ebert (A)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Marije Havermans (M)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Andrea Arricibita Varea (AA)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Michaela Fellner (M)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Dorien Pastoors (D)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Stanley van Herk (S)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Claudia Erpelinck-Verschueren (C)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Oncode Institute, Utrecht, the Netherlands.

Tim Grob (T)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Remco M Hoogenboezem (RM)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

François G Kavelaars (FG)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Daniel R Matson (DR)

Department of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin.

Emery H Bresnick (EH)

Department of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin.

Eric M Bindels (EM)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Alex Kentsis (A)

Tow Center for Developmental Oncology, Sloan Kettering Institute, Department of Pediatrics, Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York.

Johannes Zuber (J)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria.

Ruud Delwel (R)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. h.delwel@erasmusmc.nl.
Oncode Institute, Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH